Health results of SGLT2 inhibitor treatment in patients with fatty liver disease and type 2 diabetes

SGLT2 inhibitors are associated with a 65% lower risk of major clinical events in patients with MASLD and type 2 diabetes compared to DPP4 inhibitors.

• This study included 10,232 patients with MASLD and type 2 diabetes initiating either SGLT2 inhibitors or DPP4 inhibitors.
• The primary outcome assessed was a combination of all-cause mortality, major adverse cardiovascular events, kidney events, and liver outcomes.
• SGLT2 inhibitors showed a significant association with reduced risks for the composite outcome as well as for each individual component.
• Results from subgroup and sensitivity analyses were consistent with the main findings.

Simplified